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We report here that the expression of the transcription factor T-bet, which is known to 
be required for effector cytotoxic CD8+ T  lymphocytes (CTL) generation and effector 
memory cell formation, is regulated in CTL by microRNA-155 (miR-155). Importantly, 
we show that the proliferative effect of miR-155 on CD8+ T cells is mediated by T-bet. 
T-bet levels in CTL were controlled in  vivo by miR-155 via SH2 (Src homology 2)- 
containing inositol phosphatase-1 (SHIP-1), a known direct target of miR-155, and 
SHIP-1 directly downregulated T-bet. Our studies reveal an important and unexpected 
signaling axis between miR-155, T-bet, and SHIP-1 in in vivo CTL responses and sug-
gest an important signaling module that regulates effector CTL immunity.
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inTrODUcTiOn
Cytotoxic CD8+ T  cells (CTLs) are an essential component of the adaptive immune system, 
responsible for the clearance or control of cells infected with viruses or intracellular bacteria and 
tumors (1, 2). Identifying the mechanisms that control the formation of effector and memory CTL 
is essential for rational vaccine design and immunotherapeutic approaches. Transcription factors 
have been recognized as crucial elements that control and direct the fate of CTL toward effector or 
memory differentiation states (3, 4). In particular, the transcription factors T-bet, Eomes, Blimp-1, 
and Bcl-6 have been shown to regulate the differentiation and function of CTL (5). T-bet- and 
Eomes-deficient mice have shown that the “graded expression” of these transcription factors regu-
late the early effector and memory phenotype of CTL in response to infection with lymphocytic 
choriomeningitis virus (LCMV) (3). Specifically, T-bet has been linked to the generation of effector 
and effector memory CD8+ T cells (6–8) and the production of the pro-inflammatory cytokine 
IFNγ by CTL (6, 7). Therefore, understanding how T-bet expression is regulated in CTL is critical 
for our understanding of the pathways that control effector and memory CTL formation.
MicroRNAs (miRNAs) are ~22 nucleotides small, single-stranded non-coding RNAs that 
are important post-transcriptional regulators of gene expression and play essential roles in 
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modulating key cellular processes (9–11). miRNAs have been 
shown to control CD8+ T cell formation, differentiation, and 
function. In the absence of miRNA’s, CD8+ T  cells fail to 
develop normally (12) or aberrantly respond in vivo to Listeria 
monocytogenes infection (13). However, the regulatory role of 
specific miRNAs in generating effective CTL responses to viral 
infection and tumors is only now being elucidated. Indeed, the 
regulatory effect of miRNAs is not only cell-type specific, but 
also context dependent and influenced by the activation state 
of the cell and in vivo inflammatory environment (14). Thus, 
miRNA expression is expected to change depending on the 
differentiation and activation state of the CTL and this could 
also be influenced by the milieu and location in which the CTL 
response is elicited. Previous in  vitro studies have indicated 
that miRNA expression in CTL changes with differentiation 
(15) and we have shown that in vivo miR-155 expression levels 
dynamically change during differentiation from naïve to effec-
tor to memory CTL (16).
We, and others, have demonstrated that, in the absence of 
miR-155, effector CTL responses against acute infections with 
influenza A virus or L. monocytogenes, and tumors are severely 
diminished (16–19). Furthermore, in the absence of miR-155, 
the generation of memory CTL is decreased (16). This suggested 
that overexpression of miR-155 could enhance CTL responses 
to infections and cancer; indeed, we (16) and others (20) have 
found that overexpressing miR-155 in CD8+ T  cells causes 
significant expansion. Multiple mechanisms and targets by 
which miR-155-deficiency can affect CTL responses have been 
proposed including type-I IFN and STAT1/2 signaling (16), 
γc chain cytokine signaling (20), and SOCS-1 (14, 17), 
which suggests that miR-155 regulation of CTL is context 
dependent (14). This also raises the question of whether the 
overexpression of a specific miRNA targets the same mRNA as 
steady-state endogenous miRNA. Because miRNA and target 
mRNA availability is a dynamic process (21, 22), it is likely 
that supranormal levels of a miRNA may allow the targeting 
of additional mRNA which are normally outcompeted by other 
targets.
Increasing miR-155 expression in CTL augmented anti-viral 
effector CTL and skewed memory CD8+ T cells toward an effector 
memory phenotype. miR-155 overexpression induced enhanced 
T-bet expression and downregulated the inhibitory phosphatase 
SH2 (Src homology 2)-containing inositol phosphatase-1 
(SHIP-1). T-bet upregulation was necessary for effector CTL 
augmentation by miR-155. Importantly, we show that SHIP-1 
regulated T-bet expression and promoted the effector responses 
in miR-155-overexpressing CTL. Thus, T-bet expression can be 
controlled by miR-155 via SHIP-1 signaling and we have revealed 
a novel regulatory pathway for T-bet expression as well as effector 
and memory CTL generation.
MaTerials anD MeThODs
animals and infections
C57BL/6 Tg(TcraTcrb)1100Mjb/J (OT-I) were backcrossed 
with B6.SJL-Ptprca Pepcb/BoyJ (CD45.1+) mice (both from 
the Jackson Laboratory) to generate OT-I CD45.1+ mice on the 
C57BL6/J background. C57BL/6J mice, miR-155-deficient OT-I 
mice, and T-bet+/‒ OT-I mice (on the C57BL/6J background) 
were kept in a barrier facility (certified by the Association 
for the Assessment and Accreditation of Laboratory Animal 
Care) at Drexel University College of Medicine, or in a bar-
rier facility at Erasmus University Medical Center. This study 
was carried out in accordance with the recommendations of 
the Institutional Animal Care and Use Committee (IACUC) 
or the Instantie voor Dierenwelzijn (IvD). The protocols were 
approved by the IACUC or IvD. Female mice 8–10 weeks old 
were anesthetized with 2.5% isoflurane gas and were infected 
intranasally with influenza virus strain A/WSN/33-expressing 
OVA(257–264) (WSN-OVA, a gift from DJ Topham, University of 
Rochester Medical Center).
adoptive Transfer experiments
Equal numbers of sorted Thy1.1+ or GFP+ OT-I CD45.1+ cells 
(1 × 104) were intravenously transferred into CD45.2+ C57BL/6J 
wild-type recipient mice. Three h later, the recipient mice were 
anesthetized using 2.5% isoflurane gas and infected intranasally 
with influenza virus WSN-OVA.
retroviral Production
The miR-155-encoding region from the MigR1-miR-155-GFP 
vector (16) was cloned into the MSCV-IRES-Thy1.1 vector 
(provided by P. Marrack, University of Colorado). A scrambled 
control insert producing no functional miRNA was similarly 
cloned into the MSCV-IRES-Thy1.1 vector. The PINCO-empty 
vector-GFP, PINCO-SHIP-1-overexpressing-GFP, and PINCO-
D675A-SHIP-1 (SHIP-1 dominant negative) retroviral vectors 
were a kind gift from Dr. M. Caligiuri (Ohio State University) 
(23). Retroviruses were produced in the Platinum-E cell line (Cell 
Biolabs, San Diego, CA, USA).
cD8+ T-cell isolation and retroviral 
Transduction
Retroviral transduction of primary OT-I CD8+ T  cells was 
completed as previously described (16). Splenic CD8+ T cells 
were isolated by negative selection with magnetic beads 
(EasySep; Stemcell Technologies) from uninfected OT-I 
CD45.1+ female mice 8–10  weeks old. The purity of CD8+ 
T cells was >90% as determined by flow cytometry. Isolated 
CD8+ T cells were activated for 48 h using solid-phase α-CD3 
(0.25 µg/mL, clone: 17A2; eBioscience, San Diego, CA, USA) 
and α-CD28 antibodies (5 µg/mL, clone: 37.51; eBioscience) 
in 10% RPMI medium with 20  U/mL recombinant human 
IL-2 (Roche, Switzerland), 5  ng/mL of recombinant murine 
IL-7 and 5  ng/mL recombinant murine IL-15 (both from 
PeproTech, Rocky Hill, NJ, USA). Cells were collected and 
plated at a density of 3 × 106 cells per 2 mL in poly-d-lysine 
plates (ThermoFisher, Waltham, MA, USA) coated with 
20 µg/mL of Retronectin (Takara, Japan) and pre-loaded with 
retroviral supernatants. Cells were incubated for an additional 
48  h. Transduction efficiency was determined by expression 
of GFP or Thy1.1. Transduced cells were sorted with an 
FACS Aria III sorter (BD Biosciences, San Jose, CA, USA). 
Overexpression of miR-155 was confirmed by TaqMan miRNA 
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gene expression quantitative real-time polymerase chain reac-
tion (qRT-PCR) (ThermoFisher) and was determined to be 
~5-fold increased over control-transduced cells (Figure S1G 
in Supplementary Material).
Flow cytometry
Cells were stained as previously described (24). In all stains, 
cells were pretreated with anti-CD16/32 (Fc Block; 2.4G2; 
BioLegend, San Diego, CA, USA) for 15  min before continu-
ing with surface staining. For surface stains, cells were stained 
for 20  min on ice. Cells were stained with the following 
fluorochrome conjugated monoclonal antibodies: CD8a (clone 
53-6.7), CD45.1 (clone A20), CD45.2 (clone 104), Thy1.1 (clone 
HIS51) (all from eBioscience), CD25 (clone PC61), CD69 
(clone H1.2F3), CD44 (clone 1M7), CD62L (clone MEL-14) 
(all from BD Bioscience, San Jose, CA, USA), KLRG1 (clone 
2F1/KLRG1), IL-7R/CD127 (clone A7R34), and PD-1 (clone 
29F-IAI2) (all from BioLegend). Cells were also stained with 
Cy5.5-labeled Annexin V (BD Biosciences) and APC-labeled 
tetramers of H-2b major histocompatibility complex class I 
loaded with OVA(257–264). After staining, cells were washed two 
times with HBSS containing 3% FBS and 0.02% sodium azide 
and fixed with 1% PFA. For Annexin V staining, all buffers 
contained 2.5 mM CaCl2. For staining of intracellular cytokines, 
cells were stimulated with SIINFEKL peptide for 6 h at 37°C, 
5% CO2 in the presence of GolgiPlug (BD Biosciences) and 
monoclonal antibody against CD107a (clone ID4B) or isotype 
control. Cells were surface stained as above including fluoro-
chrome conjugated monoclonal antibody against CD107a (clone 
ID4B) or the appropriate isotype control (both BioLegend), 
then fixed overnight at 4°C with IC Fixation Buffer, washed 
using Perm/Wash buffer (eBioscience) and stained for intracel-
lular cytokines for 45  min at 4°C. Fluorochrome-conjugated 
anti-IFNγ monoclonal antibody (clone XMG1.2), anti-TNF-α 
monoclonal antibody (clone MP6-XT22), or the appropriate 
isotype controls (all from eBioscience) were used for intracel-
lular stains. After staining, cells were washed twice with Perm/
Wash buffer (eBioscience) and fixed with 1% PFA. For staining 
of transcription factors, cells were surface stained as above then 
fixed for 1 h at 4°C with FoxP3 Fixation Buffer, washed using 
Perm/Wash buffer (eBioscience), and stained for transcription 
factors for 1  h at 4°C. The following antibodies were used in 
combination with intracellular flow cytometry: anti-T-bet 
antibody (clone 4B10, BioLegend), anti-Eomes antibody (clone 
DAN11MAG, eBioscience), or the appropriate isotype controls. 
After staining, cells were washed twice with Perm/Wash buffer 
(eBioscience) and fixed with 1% PFA. Anti-T-bet antibody 
staining was titrated using wild-type (T-bet+/+) and T-bet+/‒ 
splenocytes to achieve clear distinction between heterozygote 
and homozygote T-bet expression (Figure S3 in Supplementary 
Material). For staining of SHIP-1, cells were surface stained as 
above, then fixed using Fixation Buffer (BioLegend) for 20 min 
at RT, washed with Perm/Wash Buffer (BioLegend), and stained 
for 20 min at RT. The following antibodies were used in combi-
nation with intracellular flow cytometry: anti-SHIP-1 antibody 
(clone P1C1-A5). After staining, cells were washed twice with 
Perm/Wash buffer (BioLegend) and fixed with 1% PFA. All 
samples were collected with an LSR-Fortessa (BD Biosciences) 
and analyzed with FlowJo software (Treestar, Ashland, OR, 
USA).
Quantitative real-time Pcr
For ex vivo measurement of miR-155, SHIP-1 (Inpp5d), T-bet 
(Tbx21), Eomes (Eomes), Blimp-1 (Prdm1), Bcl-6, (Bcl6) 
Granzyme B (gzmb) and PD-1 (Pdcd1), donor OT-I CD8+ T cells 
were sorted from the lungs or spleens of influenza virus-infected 
animals at the indicated time points. Total RNA, including 
miRNA, was extracted using the miRNeasy mini kit (Qiagen, 
Germantown, MD, USA) as per manufacturer’s instructions. 
cDNA was synthesized from 100-ng RNA with the high-capacity 
cDNA Reverse Transcription Assay (ThermoFisher). The expres-
sion of miR-155 was measured by qRT-PCR with the TaqMan 
mmu-miR-155-5p miRNA Assay (ThermoFisher). The expres-
sion of snoRNA-429 served as endogenous control. Primers for 
Inpp5d, Tbx21, Eomes, Prdm1, Bcl6, gzmb, and Pdcd1 (TaqMan 
gene expression assays all from ThermoFisher) were used to 
detect expression of these genes by qRT-PCR. Expression was 
normalized to GAPDH expression. All assays were run using 
a 7900 HT RT-PCR System. Expression was evaluated by the 
comparative cycling threshold (ΔΔCT) method.
Western Blot
Donor OT-I CD8+ T cells were sorted from the lungs of wild-
type recipient mice 9 days post-influenza virus infection, washed 
two times with 1X phosphate-buffered saline (PBS) and cell 
pellets were stored at −20°C in RIPA buffer (150-mM sodium 
chloride, 1.0% NP-40, 0.5% sodium deoxycholate, 0.1% sodium 
dodecyl sulfate, 50 mM Tris, pH 8.0). Samples were freeze-
thawed three times and then heated to 99°C on a heat block for 
10  min. Samples were loaded into a 4–12% Mini-PROTEAN 
TGX Gel (Bio-Rad, Hercules, CA, USA), then transferred at 4°C 
to PVDF membrane (EMD Millipore, Darmstadt, Germany). 
Membranes were blocked at room temperature for 1 h in 5% 
BSA in Tris-buffered saline with tween (TBST), then incubated 
overnight at 4°C with primary antibodies in TBST as follows: 
Mouse IgG1 SHIP-1 (clone: P1C1) (Santa Cruz, Dallas, TX, 
USA); Rabbit Granzyme B (cell signaling, Danvers, MA, USA); 
and Mouse β-Actin (8H10D10) (cell signaling). Membranes 
were washed, then incubated with LI-COR IRDye 800CW 
Donkey Anti-Rabbit IgG (H + L) and LI-COR IRDye 680RD 
Donkey Anti-Mouse IgG (H +  L) in 1% milk/TBST for 1  h 
at room temperature, and imaged using an Odyssey imaging 
system.
statistics
For flow cytometry and qRT-PCR data analysis, the normality of 
the population distribution was assessed using the D’Agostino-
Pearson (n = ~8 mice per group) or Shapiro–Wilk (n = <8 mice 
per group) normality test by GraphPad Prism 7. Significant 
differences between normally distributed populations were 
assessed using a two-tailed, unpaired t-test; significant differences 
between non-normally distributed populations were assessed 
using a two-tailed Mann–Whitney exact test. The subsequent 
p-values are denoted in each figure.
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resUlTs
Overexpression of mir-155 Promoting 
enhanced cD8+ T-cell responses
Previously, we demonstrated that the adoptive transfer of low 
numbers of miR-155-overexpressing OT-I cells resulted in 
increased expansion and increased viral clearance (16). To 
further understand the molecular basis of miR-155’s impact on 
CTL, we retrovirally transduced CD45.1+ OT-I CD8+ T  cells 
to overexpress miR-155 (miR-155-OE OT-I). As a control, a 
retrovirus expressing a scrambled insert was used (scrambled 
ctrl OT-I). Transduced OT-I cells were sorted and then 104 
cells were adoptively transferred into CD45.2+ recipient mice 
that were then infected with WSN-OVA influenza virus. We 
observed a significant increase in the expansion of miR-155-OE 
OT-I donor cells at day 10 post-infection in the lungs of infected 
animals in both frequency (Figure 1A) and absolute numbers 
(Figure 1B), with a 2.8-fold increase in miR-155-OE OT-I donor 
cells by day 10 (2.1 ± 0.4 × 106 versus 8.6 ± 2.3 × 106, mean ± SE 
scrambled ctrl OT-I versus miR-155-OE OT-I, respectively, 
p =  0.017). Increased expansion of miR-155-OE OT-I CD8+ 
T cells was also observed in the spleen (1.8 ± 0.3 × 106 versus 
5.3 ± 1.4 × 106, scrambled ctrl OT-I versus miR-155 OE OT-I, 
respectively, p  =  0.023) and the mediastinal lymph nodes 
(MLNs) (0.2 ± 0.4 × 105 versus 0.8 ± 0.3 × 105, scrambled ctrl 
OT-I versus miR-155 OE OT-I, respectively, p = 0.029) 10 days 
post-infection (Figures 1C,D). We similarly observed a signifi-
cant increase in the frequency and number of miR-155-OE donor 
OT-I cells in the lungs, but not in the spleen or MLN, at an earlier 
day 8 timepoint (Figures S1A,B in Supplementary Material). We 
did not observe any differences in the frequency or numbers of 
donor scrambled ctrl OT-I versus miR-155-OE OT-I cells in the 
MLN at days 5–6 post-infection indicating similar engraftment 
of donor cells (Figure S1C in Supplementary Material).
We did not observe any differences in the activation state 
(as assessed by CD25 and CD69 expression frequency and MFI) 
of donor OT-I when miR-155 was overexpressed (Figure S1D 
in Supplementary Material). Ki-67 staining of donor OT-I cells 
in the lungs at day 10 post-influenza virus infection showed 
that a greater frequency of miR-155-OE OT-I cells were Ki-67+ 
compared with scrambled ctrl OT-I cells, indicating that miR-
155 overexpression enhanced the proliferation of anti-viral CD8+ 
T cells (p = 0.022) (Figures 1E,F). A higher frequency of miR-
155-OE OT-I donor cells produced the effector cytokines IFNγ 
(60.3 ± 2.0% versus 67.7 ± 1.6%, mean ± SE donor scrambled ctrl 
OT-I versus miR-155-OE OT-I, respectively, p = 0.008) and TNFα 
(19.4 ± 2.5% versus 31.9 ± 4.4%, for donor scrambled ctrl OT-I 
versus miR-155-OE OT-I, respectively, p =  0.02) after peptide 
stimulation for 6 h (Figures 1G,H). No significant difference was 
observed in the MFI of cytokine production (data not shown). 
qRT-PCR analysis of the cytotoxic molecules granzyme A, 
granzyme B, and perforin assessed in lung donor OT-I cells 
9  days post-influenza virus infection showed no difference 
between scrambled ctrl OT-I and miR-155-OE OT-I (Figure S1E 
in Supplementary Material). Furthermore, western blot analysis 
of granzyme B protein levels confirmed no difference (Figure S1F 
in Supplementary Material). These findings demonstrate that 
increased miR-155 expression is sufficient to promote significant 
expansion and increased effector cytokine production of CTL 
during an acute influenza virus infection.
Overexpression of mir-155 skewing cD8+ 
T cells Toward an effector Memory 
Phenotype
Because miR-155 affected effector CTL responses, we also 
assessed its effect on memory CTL formation. We did not observe 
any differences in the frequencies of SLEC (short-lived effector 
cell) or MPEC (memory precursor effector cell) populations in 
donor OT-I cells in the lung or spleen 10  days post-infection 
(Figures  2A,B). We also did not observe differences in the 
frequencies or absolute numbers of donor memory OT-I CD8+ 
T cells in the lungs, spleens, or MLN (Figure S2A in Supplementary 
Material) when comparing miR-155-OE OT-I CD8+ T  cells to 
scrambled ctrl OT-I CD8+ T  cells. However, upon examina-
tion of the memory phenotype, there was skewing of spleen 
and MLN memory miR-155-OE OT-I CD8+ T cells toward the 
effector memory (TEM) phenotype (CD44+ CD62L−) compared 
with the central memory (TCM) phenotype (CD44+ CD62L+) 
(Figure 2C). The ratios of the numbers of TEM/TCM donor OT-I 
CD8+ T cells in the spleen (p = 0.02) and MLN (p = 0.005) were 
skewed to the TEM phenotype (Figure  2D) and a significantly 
lower frequency of TCM donor cells in the spleen was observed 
(p = 0.004) (Figure S2B in Supplementary Material). We observed 
no difference in the frequency of CD44+ CD62L−CD69+ CD103+ 
tissue resident memory (TRM) OT-I populations in the lungs of 
recipient mice 60  days post-influenza infection (Figure S2C in 
Supplementary Material). Unlike at day 10, we did not observe any 
difference in the frequency of IFNγ- or TNFα-producing donor 
memory miR-155-OE OT-I CD8+ T cells at day 60 (Figure S2D in 
Supplementary Material). However, we did observe an increased 
expression of CD107a (LAMP-1) (Figure S2D in Supplementary 
Material), which indicated increased degranulation of memory 
miR-155-OE OT-I CD8+ T cells.
T-Bet expression in cTl regulated by 
mir-155
The transcription factor T-bet has previously been associated 
with IFNγ production, and effector and effector memory cell 
generation in T cells during LCMV or L. monocytogenes infection 
(6, 25). We therefore examined whether miR-155 overexpression 
in CD8+ T  cells affected T-bet levels. Tbx21 (T-bet) mRNA 
levels were assessed by qRT-PCR in total RNA from scrambled 
ctrl OT-I and miR-155-OE OT-I cells sorted from the lungs on 
day 9 post-infection. This demonstrated a trending increase in 
relative T-bet mRNA levels in miR-155-OE OT-I CD8+ T cells 
(Figure 3A). To assess T-bet expression at the protein level, T-bet 
expression was measured using intracellular flow cytometry that 
was first validated by staining T-bet+/+ and T-bet+/‒ OT-I CD8+ 
T cells, which as expected (3) demonstrated half of the amount of 
T-bet after both in vitro (Figure S3A in Supplementary Material) 
and in vivo activation (Figures S3B,C in Supplementary Material). 
We found that day 10 in  vivo miR-155-OE OT-I CD8+ T  cells 
express more T-bet protein compared with scrambled ctrl OT-I 
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FigUre 1 | Continued  
Overexpression of microRNA-155 enhancing anti-viral CD8+ T-cell effector expansion. (a) Representative flow cytometry of lungs of CD45.2+ wild-type mice that 
received CD45.1+ scrambled ctrl OT-I or miR-155-OE OT-I cells. Day 10 post-influenza virus infection shown. Percentages in plots indicate percent of CD45.1+ 
donor OT-I cells among lymphocytes. (B) Numbers of lung CD45.1+ donor OT-I cells for day 10 post-infection shown. Each dot represents an individual mouse, 
n = 12–13 mice per group from at least three independent experiments. Data are normally distributed (D’Agostino-Pearson) and significance was assessed using an 
unpaired t-test. Numbers of spleen (c) and MLN (D) CD45.1+ donor OT-I cells for day 10 post-infection shown. Each dot represents an individual mouse, n = 13–15 
mice per group from at least three independent experiments. Data are normally distributed (D’Agostino-Pearson) and significance was assessed using an unpaired 
t-test. (e) Representative flow cytometry of donor OT-I cells in the lungs of influenza virus-infected animals 10 days post-infection showing gating of Ki-67− and 
Ki-67+ cells. (F) Dot plot of the frequency of Ki-67+ donor OT-I cells. Each dot represents an individual mouse, n = 4 mice per group from one experiment. Data are 
normally distributed (Shapiro–Wilk) and significance was assessed using an unpaired t-test. (g) Representative IFNγ and TNFα intracellular cytokine stains of donor 
OT-I shown on days 8 and 10 post-influenza virus infection. Numbers in top right corner indicate percent cells in each quadrant. (h) Frequency of IFNγ- and 
TNFα-producing donor OT-I cells shown. Each dot represents an individual mouse, n = 15–16 mice per group from at least three independent experiments. Data are 
normally distributed (D’Agostino-Pearson) and significance was assessed using an unpaired t-test.
FigUre 2 | Continued
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FigUre 3 | The transcription factor T-bet upregulated in miR-155-overexpressing anti-viral CD8+ T cells. (a) RT-PCR analysis of T-bet expression in donor OT-I cells 
sorted from lungs of WSN-OVA influenza virus-infected mice 9 days post-infection; results were normalized to GAPDH RNA expression and are presented relative to 
scrambled ctrl OT-I levels. Each dot represents an individual mouse, n = 4–7 mice per group from two independent experiments. Data are not normally distributed 
(Shapiro–Wilk) and significance was assessed using an unpaired Mann–Whitney exact test. (B) T-bet intracellular flow cytometry of donor cells from lungs of 
wild-type mice that received scrambled ctrl OT-I or miR-155-OE OT-I cells and assessed at day 10 after infection with influenza virus. Histogram of T-bet expression 
in donor OT-I cells shown is representative of at least three independent experiments. (c) Dot plot of T-bet expression in miR-155-OE OT-I cells relative to scrambled 
ctrl OT-I expression in donor cells from lungs of influenza virus-infected animals 9–10 days post-infection. Data are not normally distributed (D’Agostino-Pearson) 
and significance was assessed using an unpaired Mann–Whitney exact test. (D) Dot plot of T-bet expression in miR-155-OE OT-I cells relative to scrambled ctrl OT-I 
expression in donor cells in the spleen of influenza virus-infected animals 9–10 days post-infection. Data are normally distributed (D’Agostino-Pearson) and 
significance was assessed using an unpaired t-test. (e) Representative intracellular T-bet flow cytometry of OT-I, miR-155−/− OT-I, or T-bet+/− OT-I cells activated for 
7 days in vitro. (F) T-bet MFI levels in in vitro activated OT-I, miR-155−/− OT-I, or T-bet+/− OT-I cells relative to OT-I control cells. Each dot represents an individual 
mouse, n = 4–7 mice per group from three independent experiments. Data are normally distributed (Shapiro–Wilk) and significance was assessed using an unpaired 
t-test. (g) Representative histogram and (h) dot plots of T-bet expression in donor OT-I and miR-155−/− OT-I cells in the lungs of wild-type mice 10 days after 
infection with influenza virus. Data from two independent experiments, n = 5 animals per group. Data are normally distributed (Shapiro–Wilk) and significance was 
assessed using an unpaired t-test.
FigUre 2 | Continued  
Overexpression of microRNA-155 promoting effector memory formation. (a) Representative flow cytometry of CD45.1+ donor OT-I cells from lungs or spleens of 
CD45.2+ wild-type mice that received CD45.1+ scrambled ctrl OT-I or miR-155-OE OT-I cells showing SLEC (KLRG1+IL-7R−) and MPEC (KLRG1−IL-7R+) 
populations. Numbers in plots indicate percent of CD45.1+ donor OT-I cells in those populations. (B) Frequency of SLEC, MPEC, and DPEC (double-positive 
effector cells) donor OT-I cells 10 days post-infection in the lungs (top) or spleen (bottom) of recipient mice. Each dot represents an individual mouse, n = 7–8 mice 
per group from two independent experiments. Data are normally distributed (D’Agostino-Pearson) and significance was assessed using an unpaired t-test. 
(c) Representative flow cytometry of CD45.1+ donor OT-I cells from spleens or MLN of CD45.2+ wild-type mice that received CD45.1+ scrambled ctrl OT-I or 
miR-155-OE OT-I cells day 60 after infection with influenza virus. Numbers in plots indicate percent of CD45.1+ donor OT-I cells in the TEM (CD44+ CD62L−) and TCM 
(CD44+ CD62L+) compartments. (D) Ratio of the absolute number of TEM/TCM donor OT-I cells in the spleen (top) and MLN (bottom) shown. Each dot represents an 
individual mouse, n = 8–9 mice per group from two independent experiments. Data are normally distributed (D’Agostino-Pearson) and significance was assessed 
using an unpaired t-test.
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FigUre 4 | MicroRNA-155-mediated expansion of anti-viral CTL mediated by T-bet. (a) Representative flow cytometry of lungs of CD45.2+ wild-type mice that 
received CD45.1+ scrambled ctrl or miR-155-OE transduced T-bet+/− or wild-type OT-I cells. Day 10 post-influenza virus infection shown. Percentages in plots 
indicate percent of CD45.1+ donor OT-I cells among lymphocytes. Dot plot showing fold-change in donor OT-I cell numbers relative to scrambled ctrl OT-I cell 
numbers in the lungs (B), spleen (c), or MLN (D) of recipient mice 10 days post-infection with influenza virus. Data are normally distributed (D’Agostino-Pearson) 
and significance was assessed using an unpaired t-test.
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in the lungs (p =  0.01) (Figures 3B,C) and spleen (p =  0.005) 
(Figure  3D), indicating that T-bet expression in miR-155-OE 
OT-I CD8+ T cells may be regulated at the translational level as a 
significant difference was observed only at the protein level and 
not at the level of mRNA.
Since miR-155-overexpressing CTLs have increased amounts 
of T-bet, we reasoned that conversely miR-155-deficient CD8+ 
T  cells would express decreased levels of T-bet. To assess this, 
splenic miR-155−/− OT-I CD8+ T cells were isolated and activated 
in  vitro with plate-bound α-CD3 and α-CD28 antibodies and 
cultured for 7 days. In parallel, wild-type T-bet-sufficient OT-I 
CD8+ T  cells and T-bet heterozygote (T-bet+/‒) OT-I CD8+ 
T cells were similarly cultured. We found that T-bet+/‒ OT-I cells 
exhibited a gene-dosage effect and expressed half the amount 
of T-bet compared with wild-type OT-I cells (Figures  3E,F). 
T-bet staining of miR-155−/− OT-I CD8+ T cells revealed a 40% 
(p = 0.0001) reduction in T-bet expression relative to wild-type 
OT-I CD8+ T  cells (Figure  3F). Adoptively transferred miR-
155−/− OT-I cells exhibited significantly decreased T-bet levels 
compared with wild-type OT-I cells 10 days post-influenza virus 
infection (p = 0.008) (Figures 3E,G,H). These data provide the 
first evidence that miR-155 regulates T-bet expression in CTL. 
Furthermore, miR-155-overexpressing anti-viral CD8+ T  cells 
demonstrate increased levels of T-bet, and thus enhanced 
T-bet expression may be responsible for the augmented effector 
generation and effector memory phenotype observed.
To directly test if increased T-bet in miR-155-OE OT-I cells 
was responsible for augmenting effector generation of anti-viral 
CTL, T-bet+/‒ OT-I or wild-type T-bet+/+ OT-I CD8+ T cells were 
retrovirally transduced to overexpress miR-155 or the scrambled 
sequence. Transduced cells were then adoptively transferred into 
host mice followed by infection with WSN-OVA influenza virus. 
miR-155-overexpressing T-bet+/‒ OT-I CD8+ T  cells (T-bet+/‒ 
miR-155-OE OT-I) were incapable of expanding to the same 
capacity as miR-155-OE OT-I at day 10 post-infection in the lungs 
of influenza virus-infected animals (p = 0.012) (Figures 4A,B). 
A similar effect was observed in the spleen (p = 0.006), but not the 
MLN (Figures 4C,D). These data demonstrate that T-bet is essen-
tial to drive the increased expansion of miR-155-overexpressing 
CD8+ T cells during influenza virus infection.
Overexpression of mir-155 altering the 
Transcription Factor Profile of Memory 
cD8+ T cells enhancing the expression of 
T-Bet and Blimp-1
Since transcription factors such as T-bet, Eomes, Blimp-1, 
and Bcl-6 are important regulators of CD8+ T-cell memory 
FigUre 5 | Overexpression of microRNA-155 altering the transcription factor profile of memory anti-viral CTL. (a) RT-PCR analysis of Blimp-1, Bcl-6, T-bet, and 
Eomes expression in TCM (CD44+ CD62L+) or TEM (CD44+ CD62L−) CD45.1+ CD8+ OT-I donor cells sorted from the spleens of CD45.2+ wild-type mice 60 days 
post-infection with WSN-OVA influenza virus. Expression levels are represented relative to the scrambled ctrl OT-I expression level within each subset. Data from two 
independent experiments, n = 2–3 mice per group. (B) Representative histograms and (c) dot plots of intracellular T-bet flow cytometry of CD44+ CD62L+ TCM and 
CD44+ CD62L− TEM cells in spleens of wild-type mice that received scrambled ctrl OT-I or miR-155-OE OT-I cells. Day 60 after infection with influenza virus shown. 
Data from two independent experiments, n = 4–5 animals per group. T-bet expression is shown relative to scrambled ctrl OT-I.
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generation (4) and miR-155 overexpression promoted effector 
memory CTL formation, we examined the transcription factor 
profile of miR-155-overexpressing memory CTL. To assess this, 
TCM and TEM donor cell compartments were sorted 60 days post-
influenza virus infection and mRNA expression levels of Tbx21 
(encoding T-bet), Eomes, Prdm1 (encoding Blimp-1), and Bcl6 
were measured. We observed that Blimp-1 mRNA expression was 
modestly increased in miR-155-OE TEM OT-I cells, while Bcl-6 
mRNA expression was decreased in miR-155-OE TEM OT-I cells 
compared with scrambled ctrl OT-I CD8+ T  cells (Figure  5A, 
top). Interestingly, we observed in both TEM and TCM compart-
ments an increase in T-bet mRNA expression when miR-155 
was overexpressed, with the greatest increase observed in the 
TCM compartment (Figure 5A, bottom). We did not observe any 
differences in Eomes mRNA expression. Intracellular staining 
and flow cytometry confirmed increased T-bet expression when 
miR-155 was overexpressed in both TEM and TCM compartments 
in the spleen (Figures 5B,C).
FigUre 6 | SHIP-1 downregulated by miR-155 in anti-viral CTL. (a) RT-PCR analysis of SHIP-1 levels in donor OT-I cells sorted from lungs 9 days post-infection 
with WSN-OVA influenza virus. Results were normalized to GAPDH RNA expression and are presented relative to scrambled ctrl OT-I expression levels. Each dot 
represents an individual mouse, n = 4–6 mice per group from two independent experiments. Data are normally distributed (Shapiro–Wilk) and significance was 
assessed using an unpaired t-test. (B) Western blot analysis of SHIP-1 expression in sorted donor scrambled ctrl or miR-155-OE OT-I cells. Representative of three 
mice per group. (c) Representative histogram of intracellular SHIP-1 flow cytometry of donor OT-I cells from lungs 9–10 days post-infection with influenza virus. 
Histograms gated on CD45.1+ donor cells. (D) SHIP-1 MFI expression levels relative to scrambled ctrl OT-I expression levels. Each dot represents an individual 
mouse, n = 11 mice per group from three independent experiments. Data are normally distributed (D’Agostino-Pearson) and significance was assessed using an 
unpaired t-test.
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mir-155 regulating shiP-1 expression in 
anti-Viral cD8+ T cells Modulating T-Bet 
levels
As T-bet is not predicted to be a direct target of miR-155, we 
reasoned that miR-155 was regulating T-bet expression indi-
rectly. SHIP-1 has previously been identified as a direct target of 
miR-155 and has been reported to be affected by miR-155 in CTL 
(16, 20, 26). We assessed SHIP-1 expression at both the mRNA 
and protein levels when miR-155 is overexpressed in CTL. qRT-
PCR of sorted day 9 post-influenza virus infection miR-155-OE 
OT-I cells showed a 25% decrease in SHIP-1 (Inpp5d) mRNA 
expression levels (Figure 6A) compared with controls. Western 
blot analysis (Figure 6B) and intracellular flow cytometry stain-
ing (Figures 6C,D) of miR-155-OE OT-I CD8+ T cells revealed 
that miR-155 overexpression resulted in significantly decreased 
(p <  0.0001) SHIP-1 protein expression in anti-viral CTL on 
days 9–10 post-influenza virus infection, demonstrating that like 
T-bet, SHIP-1 expression is modulated at the translational level 
in miR-155-OE CD8+ T cells. As miR-155 overexpression led to 
decreased SHIP-1 protein expression and microarray analysis 
had previously identified a modest (1.20-fold, p  =  0.01) 
upregulation of SHIP-1 mRNA in miR-155-deficient CTL after 
3  days of in  vitro activation (16), we sought to assess SHIP-1 
protein expression in miR-155-deficient CTL. Intracellular flow 
cytometry confirmed that miR-155−/− OT-I cells cultured in vitro 
for 7 days expressed significantly more SHIP-1 compared with 
wild-type control cells (1.45-fold increase of MFI, p =  0.005) 
(Figures 7A,B). Adoptively transferred miR-155−/− OT-I cells also 
demonstrated significantly increased SHIP-1 levels compared with 
wild-type OT-I cells 10 days post-infection with influenza virus 
(p = 0.032) (Figures 7C,D). Finally, we tested if SHIP-1 directly 
mediates the effect of miR-155 on T-bet expression. OT-I cells 
were transduced with either an SHIP-1-overexpressing retrovirus 
(SHIP-1-OE OT-I) or a dominant-negative SHIP-1 resulting in 
the inhibition of SHIP-1 signaling (23) (SHIP-1DN OT-I) and 
adoptive transfers were performed. We show that SHIP-1 over-
expression alone is sufficient to decrease T-bet relative to control 
levels (Figures  7E,F), while SHIP-1-DN results in significantly 
increased T-bet expression levels in donor OT-I cells (p = 0.013) 
(Figure 7G). Taken together, these data provide further support 
that miR-155 modulates T-bet expression via SHIP-1.
DiscUssiOn
The importance of miRNA in T cells, particularly CD8+ T cells, 
has been demonstrated with Dicer-deficient animals (12, 13, 
27), where the lack of mature miRNA has profound effects 
on the differentiation and function of T  cells. Since miR-155 
is upregulated in effector CTL and we have previously shown 
that the absence of miR-155 significantly reduces effective 
CTL responses to infection (16), we argued that its forced 
overexpression would enhance the CTL response. Indeed, 
overexpression of miR-155 in CTL augmented the response, 
in agreement with previous reports from us and others (16, 17, 
20). In exploring the mechanistic underpinnings of the effect of 
miR-155 overexpression, we have revealed an unexpected con-
nection between miR-155 and T-bet expression in virus-specific 
CD8+ T cells, mediated through the SHIP-1-signaling pathway. 
miR-155 has been shown, by us and others, to control the CTL 
immune response (14, 16–20), while the direct targets by which 
FigUre 7 | T-bet expression regulated by SHIP-1 in anti-viral CTL. (a) Representative histogram of intracellular SHIP-1 flow cytometry of OT-I or miR-155−/− OT-I 
cells activated for 7 days in vitro with solid plate-bound α-CD3/α-CD28 antibodies. (B) SHIP-1 MFI levels in in vitro activated OT-I or miR-155−/− OT-I cells relative to 
OT-I control cells. Each dot represents an individual mouse, n = 10 mice per group from four independent experiments. Data are normally distributed (D’Agostino-
Pearson) and significance was assessed using an unpaired t-test. (c) Representative histogram and (D) dot plots of intracellular SHIP-1 flow cytometry of lung donor 
OT-I or miR-155−/− OT-I cells on day 10 post-infection with influenza virus. Data from n = 5–7 mice per group and two independent experiments shown. Data are 
normally distributed (Shapiro–Wilk) and significance was assessed using an unpaired t-test. (e) Representative histograms and (F) dot plots of intracellular T-bet flow 
cytometry of lung vector ctrl OT-I or SHIP-1-OE OT-I cells on day 10 post-influenza virus infection. T-bet MFI expression levels relative to vector ctrl OT-I expression 
levels. Each dot represents an individual mouse, n = 3–4 mice per group from two independent experiments. Data are normally distributed (Shapiro–Wilk) and 
significance was assessed using an unpaired t-test. (g) T-bet MFI expression levels in SHIP-1DN or vector-transduced donor OT-I CD8+ T cells 10 days post-
infection with WSN-OVA influenza virus in the spleen. Expression is shown relative to vector ctrl OT-I expression levels. Each dot represents an individual mouse, 
n = 7 mice per group from two independent experiments. Data are normally distributed (Shapiro–Wilk) and significance was assessed using an unpaired t-test.
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miR-155 affects CTL responses have been suggested to be con-
text dependent (14). Previous studies have indicated that miR-
155 in CD8+ T cells may regulate SOCS-1 and STAT5 in acute 
and chronic LCMV infection (17) and tumors (17, 20), STAT1/
STAT2 and type I IFN signaling in influenza virus infection (16), 
and c-maf in CD4+ T cells (28) depending on the cell type and 
the environment in which the response is taking place. To the 
best of our knowledge, this is the first report that miR-155 can 
regulate T-bet expression in CTL and miR-155 overexpression 
leads to increased numbers of effector CTL and a skewing of 
CTL memory to an effector memory phenotype. This is consist-
ent with T-bet’s well-known capacity to promote effector CTL 
expansion and effector memory CD8+ T-cell generation. Indeed, 
we find that the increased effector CTL expansion is induced 
by miR-155 overexpression and is mediated by T-bet as miR-
155-overexpressing T-bet+/‒ CTL fail to expand.
In CD8+ T cells, T-bet promotes the differentiation of effector 
CTL and is associated with TEM CD8+ T cells (3). In the absence 
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of T-bet during a viral infection such as LCMV, CTL differentia-
tion was skewed toward a KLRG1loCD127hi memory precursor 
phenotype with less formation of terminally differentiated 
effector cells (3), and memory CD8+ T cells are maintained (29). 
Overexpression of T-bet sustains effector CTL during chronic 
LCMV infection (30). Because T-bet mRNA 3′UTR lacks a 
miR-155 seeding sequence and is not a known or predicted 
target of miR-155, we postulated that this is an indirect effect. 
Indeed, we report that the modulation of T-bet levels by miR-155 
is mediated by miR-155’s direct target SHIP-1. The relationship 
between SHIP-1 and T-bet has been previously demonstrated by 
Tarasenko et al. who observed that SHIP-1-deficient CD8+ T cells 
expressed 60% more T-bet than control CD8+ T cells (31). This 
raises the question of how SHIP-1 signaling negatively affects 
T-bet levels. One pathway that is well established to control 
T-bet expression is mTOR signaling (8), which is downstream 
of phosphatidylinositol-3-kinase (PI3K) signaling (32). SHIP-1 
is known to inhibit PI3K signaling (33), which would result in 
reduced mTOR activity and decreased T-bet. miR-155, by sup-
pressing SHIP-1 levels, may amplify PI3K and mTOR signaling, 
thus resulting in more T-bet. Future studies examining the PI3K 
pathway when miR-155 is modulated could address this question.
Here, we report that SHIP-1 can be downregulated in CTL 
as a result of miR-155 overexpression, while miR-155 deficiency 
leads to increased SHIP-1 levels. SHIP-1 is a bona fide direct 
target of miR-155 and this downregulation has been shown to 
play an important functional role in many immune cell subsets 
including macrophages (26), NK  cells (34), and dendritic cells 
(35) and SHIP-1 levels have been reported to be modulated in 
CTL by miR-155 overexpression (20). In our current study, we 
demonstrate that this intrinsic SHIP-1 modulation impacts CTL 
responses. Although the role of SHIP-1 in immune cells has been 
extensively studied, the role of SHIP-1 in T cells is less clear. There 
is conflicting data regarding how SHIP-1 expression impacts 
the ratio of peripheral CD4+ and CD8+ T-lymphocyte popula-
tions (31, 36), and the role of SHIP-1 in in vivo CTL responses 
is questionable. In a previous study by Tarasenko et al., the role 
of SHIP-1 in T  cells was explored using a CD4cre SHIPfl/fl mice 
in which all T cells lacked SHIP-1 expression. Although a Th1 
skewing of CD4+ T cells was observed, no differences were found 
in the in vivo expansion of SHIP-deficient CD4+ or CD8+ T cells 
in mice immunized with ovalbumin (31). However, SHIP-1 
may play an important role in CTL in the inflammatory milieu 
of a viral infection, where dampening inflammatory signaling 
pathways may be critical for the CTL responses. Alternatively, 
the effect of SHIP-1 on CTL that overexpress miR-155 may be due 
to additional miR-155-mediated perturbations in other signaling 
pathways that change the balance between signaling pathways 
and raise SHIP-1 to a more prominent functional role.
We find that miR-155 overexpression also affects memory 
CTL responses. We found that TEM CTL formation was favored 
by miR-155 overexpression. Indeed, we previously observed 
that miR-155 was more highly expressed in anti-viral TEM versus 
TCM (16). This most likely is due to miR-155 overexpression 
increasing T-bet expression as T-bet is known to promote TEM 
CTL formation (8, 37). However, miR-155 overexpression also 
increased Blimp-1 and decreased Bcl-6 in memory cells. Thus, 
the promotion of TEM CTL formation could be due to changes in 
several transcriptional factors that affect TEM CTL. Interestingly, 
we found that miR-155-overexpressing TCM CTL also increased 
T-bet expression in the spleen. Since the numbers of TEM and TCM 
CTL were not increased in spleens, it is possible that increased 
T-bet levels in TCM promotes their conversion to TEM, a dynamic 
process previously observed in vesicular stomatitis virus (VSV)-
specific and L. monocytogenes-specific memory CTL (38, 39), and 
leads to their preferential migration to sites of inflammation such 
as the lung or MLN. This is consistent with T-bet’s ability to drive 
TEM formation but also suggests that miR-155 overexpression 
could regulate plasticity of CTL memory phenotypes.
We report here that miR-155 overexpression leads to increased 
effector CTL responses and a skewing of memory CTL toward an 
effector memory phenotype. To the best of our knowledge, our 
studies conclusively show for the first time a novel connection 
between miR-155 and T-bet in CD8+ T cells. The link between 
miR-155 overexpression and T-bet upregulation is essential for 
the expansion of effector CTL. We show that T-bet is indirectly 
targeted by miR-155 via miR-155’s repression of its direct target 
SHIP-1. Our studies reveal an unexpected miR-155/SHIP-1/T-
bet axis in CTL immunity to viral infection that may play a pivotal 
role in CTL immunity in the context of infection and cancer.
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